The U.S. Food and Drug Administration said Friday it has granted accelerated approval for Tagrisso as a treatment for patients with advanced non-small cell lung cancer. The drug is marketed by AstraZeneca Plc . The approval is for patients whose tumors have an epidermal growth factor receptor mutation (EGFR) T790M, and who have deteriorated after being treated with other EGFR-blocking therapy, the FDA said in a statement. Lung cancer is the leading cause of death by cancer in the U.S., with about 158,040 deaths in 2015 so far, and about 221,200 new diagnoses. AstraZeneca ADRs were trading up 0.2%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News